Navigation Links
Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting
Date:4/16/2008

PRINCETON, N.J., April 16 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today data from a Phase 1/2 trial that suggest a potential association between higher doses of MDX-060, an investigational anti-CD30 antibody, and improvement in disease control and prolonged progression-free survival in patients with relapsed or refractory CD30- positive lymphomas. Results from the Phase 1/2 trial were presented at the Annual Meeting of the American Association for Cancer Research (AACR), being held April 12-16, 2008 in San Diego (Abstract #5525).

"We continue to assess the potential for anti-CD30 antibody therapies in the marketplace and are pleased with the findings of this exploratory study," said Howard H. Pien, President and CEO of Medarex. "We look forward to analyzing these results alongside the Phase 2 proof-of-concept chemotherapy combination data that is expected later in the year."

In the completed dose-escalation Phase 1/2 trial, 72 patients with relapsed or refractory CD30-positive lymphoma received weekly doses of MDX-060 (0.1, 1, 4, 10 or 15 mg/kg) for four weeks. Of the 33 patients treated at the two highest doses of MDX-060, disease control was observed in 51 percent of patients (3 complete responses, 14 stable disease), with median progression- free survival of 3.7 months and 39 percent of patients with no evidence of disease progression four months post-treatment. Of the 39 patients treated at the three lowest doses of MDX-060, disease control was observed in 33 percent of patients (1 complete response, 2 partial responses, 10 stable disease), with median progression-free survival of less than 2 months and 18 percent of patients with no evidence of disease progression four months post-treatment. MDX
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
2. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
3. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
4. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
5. Medarex to Present at the UBS Global Life Sciences Conference
6. Medarex Announces Election of Marc Rubin as New Board Member
7. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
8. Medarex Announces Completion of Sale of Shares in Genmab A/S
9. Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
10. Medarex to Present at the Susquehanna Financial Group Healthcare Conference
11. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2013)... 25, 2013 Significant research in quantum ... been recognized with presentation of awards by the ... made 16 April during the SPIE Optics and Optoelectronics ... for optics and photonics , is an International Society ... University was presented with the 2011 ICO Galileo Galilei ...
(Date:5/25/2013)... Dennis R. HIll M.D. Radiation Oncologist at ... that recently there has been a promotion of the idea ... permanent seed, or low dose rate, brachytherapy for prostate cancer. ... energy, a shorter half life, and gives a higher biologically ... 131 has a higher average energy than the other commonly ...
(Date:5/24/2013)... Dr. Ingrid Warmuth and Anamaria Newport, MHS, PA-C, with ... announce an Open House at their Swedesboro location, 95 Woodstown ... from 10 AM to 2 PM. , During the ... will be on hand to talk to people about the ... complimentary cosmetic consultations. There will also be specials offered, such ...
(Date:5/24/2013)... WA (PRWEB) May 24, 2013 ... engineers, and industry suppliers will present technologies with ... at the annual SPIE Optics and Photonics ... Organized by SPIE, the international society for ... largest international, multidisciplinary optical sciences and technology meeting ...
Breaking Biology Technology:ICO Honors Three with Awards during SPIE Optics and Optoelectronics 2ICO Honors Three with Awards during SPIE Optics and Optoelectronics 3Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Compares Prostate Cancer Treatment Options: Not All Low Dose Rate Brachytherapy Isotopes Are the Same 2Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Compares Prostate Cancer Treatment Options: Not All Low Dose Rate Brachytherapy Isotopes Are the Same 3See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 2See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 3See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 4
... Mass. and CLEARWATER, Fla., Sept. 10 ... whole blood analyzers, and CCS Medical, Inc. a leading ... have reached a definitive agreement under which Nova Biomedical,s ... certain assets of Sanvita, Inc., a wholly-owned subsidiary of ...
... , , HOUSTON, ... a provider agreement with Beech Street Corporation, one of the ... Beech Street will assist SpectraCell with the ever-increasing administrative needs ... , , Beech Street addresses the ...
... , , HORSHAM, Pa., ... today announced that it received a Complete Response letter from ... Drug Application (NDA) for trabectedin when administered in combination with ... the treatment of women with relapsed ovarian cancer. The ...
Cached Biology Technology:Nova Biomedical and CCS Medical Reach Definitive Agreement for a Subsidiary of Nova Biomedical to Acquire Assets of CCS Medical's Subsidiary, Sanvita Inc. 2Nova Biomedical and CCS Medical Reach Definitive Agreement for a Subsidiary of Nova Biomedical to Acquire Assets of CCS Medical's Subsidiary, Sanvita Inc. 3SpectraCell Contracts With Beech Street Corporation 2FDA Issues Complete Response Letter For Trabectedin Combined With DOXIL 2
(Date:5/24/2013)... Studying complex systems like ecosystems can get messy, especially ... big unknowns like climate change. , In a ... Proceedings of the National Academy of Sciences , ... a fundamental assumption at the very heart of a ... To model how climate changes may impact biodiversity, researchers ...
(Date:5/24/2013)... frequently expressed concern in the ongoing public health debate ... those that are nutrient dense. A new study, ... Most Nutrients Per Penny," published in the journal ... the best nutritional values in the produce aisle, providing ... most other raw vegetables and delivering one of the ...
(Date:5/24/2013)... of the world,s largest and fastest growing open-access publishers, ... Frontiers in Physics . , A broad scope journal ... provide an open-science and interactive web platform for the ... articles. , Frontiers, real-time and interactive peer-review enables ... article types. With an average of three months from ...
Breaking Biology News(10 mins):Understanding the past and predicting the future by looking across space and time 2New research shows that potatoes provide one of the best nutritional values per penny 2Frontiers launches new open-access journal in physics 2Frontiers launches new open-access journal in physics 3
... Salts Emerging as New Recreational Drugs, (#1120069, Wednesday, ... bath salts as recreational drugs has greatly escalated in ... Sciences Center in Oklahoma City, Oklahoma describe an incident ... who also exhibited violent behavior upon his emergency department ...
... Exposure in the womb to bisphenol A (BPA) ... other consumer goods is associated with behavior and ... led by researchers at Harvard School of Public Health ... Fraser University in Vancouver, British Columbia. BPA ...
... identifying ideal drug combinations from billions of others which ... in Nature Chemical Biology , could be the ... to combat severe diseases and conditions. Most non-infectious ... by inflammation, which is the body,s natural defence mechanism. ...
Cached Biology News:CHEST 2011: Embargoed studies highlight new lung health research 2CHEST 2011: Embargoed studies highlight new lung health research 3CHEST 2011: Embargoed studies highlight new lung health research 4CHEST 2011: Embargoed studies highlight new lung health research 5CHEST 2011: Embargoed studies highlight new lung health research 6Exposure to chemical BPA before birth linked to behavioral, emotional difficulties in girls 2Manchester's 'first step' to perfect drug combinations 2
... NOS assay kit measures NOS activity by ... citrulline. This assay is simple, sensitive, and ... used with both crude and purified enzyme ... reagents for 50 total reactions. Radiolabeled arginine ...
Human Complement Component C5a MAb (Clone 295003)...
Human OSCAR MAb (Clone 259501)...
Homo sapiens retinoid X receptor, alpha...
Biology Products: